The Global Peptide Therapeutics Market was valued at USD 46.4 billion in 2024 and is estimated to grow at a CAGR of 8.1% to reach USD 100 billion by 2034.
The increasing prevalence of chronic and lifestyle-related diseases, including diabetes, cancer, and obesity, is a significant growth driver. Peptide therapeutics, composed of short chains of amino acids, target specific molecular pathways, offering high efficacy and reduced side effects compared to conventional therapies. These treatments are applied across diverse therapeutic areas such as metabolic disorders, cardiovascular diseases, gastrointestinal conditions, infectious diseases, cancer, and rare genetic disorders. The integration of electronic health records, AI-based clinical decision-making tools, and real-world evidence platforms is reshaping the development, monitoring, and prescription of peptide therapies. Government programs and public-private partnerships enhancing access to molecular diagnostics, personalized medicine, and rare disease treatments further accelerate growth. With rising demand for biologically inspired and precision medicines, peptide therapeutics are emerging as critical solutions in modern healthcare due to their safety, specificity, and wide-ranging therapeutic potential.
The branded peptides segment held a 69.2% share in 2024, driven by its strong focus on innovation, high specificity, and proven clinical efficacy. These therapies are increasingly preferred for the treatment of complex and chronic conditions, where precise targeting and minimal off-target effects are essential. Branded peptides benefit from robust research and development pipelines, continuous formulation improvements, and advanced delivery mechanisms, which enhance patient outcomes and therapeutic reliability.
The parenteral segment generated USD 30.8 billion in 2024, owing to the poor stability and low oral bioavailability of peptides, making intravenous, subcutaneous, or intramuscular administration the preferred delivery method. Parenteral delivery ensures rapid absorption, accurate dosing, and high efficacy for critical indications such as metabolic disorders, cancer, and rare endocrine conditions.
North America Peptide Therapeutics Market held a 42.1% share in 2024. Growth in the region is fueled by advanced biopharmaceutical infrastructure, early regulatory approvals, strong R&D investments, and the rising prevalence of cancer, metabolic disorders, and rare diseases. The development of branded and innovative peptide therapies in countries like the U.S. and Canada supports demand for targeted, low-toxicity treatments.
Key players in the Global Peptide Therapeutics Market include Novo Nordisk, PolyPeptide Group, Rhythm Pharmaceuticals, Ascendis Pharma, Zydus Lifesciences, Ferring Pharmaceuticals, AstraZeneca, X-GEN Pharmaceuticals, Eli Lilly and Company, Repligen Corporation, Sanofi, Amgen, Bristol-Myers Squibb, PeptiDream, and Merck & Co. Companies in the Peptide Therapeutics Market are adopting strategies such as investing in research and development to create novel peptide formulations, collaborating with biotech startups to accelerate innovation, and forming strategic alliances for global distribution. Many firms focus on expanding their product portfolios to cover rare and chronic diseases while enhancing manufacturing capabilities for high-purity peptides. Market participants are increasingly leveraging digital platforms and AI for precision drug development, patient monitoring, and real-world data collection.
This product will be delivered within 2-4 business days.
The increasing prevalence of chronic and lifestyle-related diseases, including diabetes, cancer, and obesity, is a significant growth driver. Peptide therapeutics, composed of short chains of amino acids, target specific molecular pathways, offering high efficacy and reduced side effects compared to conventional therapies. These treatments are applied across diverse therapeutic areas such as metabolic disorders, cardiovascular diseases, gastrointestinal conditions, infectious diseases, cancer, and rare genetic disorders. The integration of electronic health records, AI-based clinical decision-making tools, and real-world evidence platforms is reshaping the development, monitoring, and prescription of peptide therapies. Government programs and public-private partnerships enhancing access to molecular diagnostics, personalized medicine, and rare disease treatments further accelerate growth. With rising demand for biologically inspired and precision medicines, peptide therapeutics are emerging as critical solutions in modern healthcare due to their safety, specificity, and wide-ranging therapeutic potential.
The branded peptides segment held a 69.2% share in 2024, driven by its strong focus on innovation, high specificity, and proven clinical efficacy. These therapies are increasingly preferred for the treatment of complex and chronic conditions, where precise targeting and minimal off-target effects are essential. Branded peptides benefit from robust research and development pipelines, continuous formulation improvements, and advanced delivery mechanisms, which enhance patient outcomes and therapeutic reliability.
The parenteral segment generated USD 30.8 billion in 2024, owing to the poor stability and low oral bioavailability of peptides, making intravenous, subcutaneous, or intramuscular administration the preferred delivery method. Parenteral delivery ensures rapid absorption, accurate dosing, and high efficacy for critical indications such as metabolic disorders, cancer, and rare endocrine conditions.
North America Peptide Therapeutics Market held a 42.1% share in 2024. Growth in the region is fueled by advanced biopharmaceutical infrastructure, early regulatory approvals, strong R&D investments, and the rising prevalence of cancer, metabolic disorders, and rare diseases. The development of branded and innovative peptide therapies in countries like the U.S. and Canada supports demand for targeted, low-toxicity treatments.
Key players in the Global Peptide Therapeutics Market include Novo Nordisk, PolyPeptide Group, Rhythm Pharmaceuticals, Ascendis Pharma, Zydus Lifesciences, Ferring Pharmaceuticals, AstraZeneca, X-GEN Pharmaceuticals, Eli Lilly and Company, Repligen Corporation, Sanofi, Amgen, Bristol-Myers Squibb, PeptiDream, and Merck & Co. Companies in the Peptide Therapeutics Market are adopting strategies such as investing in research and development to create novel peptide formulations, collaborating with biotech startups to accelerate innovation, and forming strategic alliances for global distribution. Many firms focus on expanding their product portfolios to cover rare and chronic diseases while enhancing manufacturing capabilities for high-purity peptides. Market participants are increasingly leveraging digital platforms and AI for precision drug development, patient monitoring, and real-world data collection.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Type, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Route of Administration, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Manufacturer Type, 2021-2034 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Synthesis Technology, 2021-2034 ($ Mn)
Chapter 10 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 11 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 12 Company Profiles
Companies Mentioned
The companies featured in this Peptide Therapeutics market report include:- Amgen
- Ascendis Pharma
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly and Company
- Ferring Pharmaceuticals
- Merck & Co.
- Novo Nordisk
- PeptiDream
- PolyPeptide Group
- Repligen Corporation
- Rhythm Pharmaceuticals
- Sanofi
- X-GEN Pharmaceuticals
- Zydus Lifesciences
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 142 |
| Published | November 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 46.4 Billion |
| Forecasted Market Value ( USD | $ 100 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
